This Article Free Full Text (Free PDF) Free A correction has been published References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Tornatore, C. Articles by Clifford, D. B PubMed PubMed Citation Articles by Tornatore, C. Articles by Clifford, D. B Social Bookmarking                         What's this?

Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use

Department of Neurology, Director, Multiple Sclerosis Center, Georgetown University Medical Center, Washington, DC, USA, tornatoc{at}gunet.georgetown.edu

David B Clifford

Department of Clinical Neuropharmacology in Neurology and Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

Natalizumab therapy for patients with multiple sclerosis (MS) has been associated with both improved clinical outcomes and an increased incidence of progressive multifocal leukoencephalopathy (PML). We provide details of the etiology and recent history of PML as associated with immunosuppressive disease states, including MS. Furthermore, it offers clinical guidance on differentiating PML from a MS relapse and a review of the current treatment options for patients suspected of having developed the complication.

Key Words: progressive multifocal leukoencephalopathy • multiple sclerosis • natalizumab

Multiple Sclerosis, Vol. 15, No. 4 Suppl, S16-S25 (2009)
DOI: 10.1177/1352458509347130


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?